Burgess M M
Office of Medical Bioethics, University of Calgary, Alberta, Canada.
Alzheimer Dis Assoc Disord. 1994;8(2):71-8. doi: 10.1097/00002093-199408020-00004.
This article discusses an ethics research project in predictive testing for Huntington's disease (HD) and the relevance of the findings for genetic testing for Alzheimer's disease (AD). Participants were videotaped during their pre- and posttest counseling sessions, as well as when the results were given. Half of these were then interviewed in their homes. Changes that accompanied the receipt of decreased risk suggested that counseling as well as the genetic information led the participants through a rite of passage. The most significant changes seemed to be in relation to other family members. Application to persons at risk for AD needs to be qualified, since persons at risk for AD will not usually have as well developed a sense of "family risk," and are less likely to receive as definite a reduced risk. In diagnostic testing for AD, a substitute decision-maker will often be involved. An unavoidable result is that some of the related substitute decision-makers will receive results which may have, or be mistaken to have, predictive value. Substitute decision-makers must therefore be included in genetic counseling, and the psychosocial effects of their participation must be evaluated.
本文讨论了一项关于亨廷顿舞蹈症(HD)预测性检测的伦理研究项目,以及研究结果与阿尔茨海默病(AD)基因检测的相关性。在参与者进行检测前和检测后的咨询过程中,以及在告知检测结果时,对他们进行了录像。其中一半人随后在其家中接受了访谈。风险降低带来的变化表明,咨询以及基因信息引导参与者经历了一个人生转折仪式。最显著的变化似乎与其他家庭成员有关。将其应用于AD风险人群时需要谨慎,因为AD风险人群通常不会有同样强烈的“家族风险”意识,而且获得明确风险降低的可能性较小。在AD的诊断检测中,通常会涉及替代决策者。一个不可避免的结果是,一些相关的替代决策者会收到可能具有或被误认为具有预测价值的结果。因此,替代决策者必须纳入基因咨询,并且必须评估他们参与所产生的社会心理影响。